59 results about "Bone marrow source" patented technology

This invention relates to a method of inhibiting the overactivity of phagocytes or lymphocytes in an individual by administering to said individual an effective amount of a lignan, wherein i) the phagocytes are neutrophils and the lignan is hydroxymatairesinol or matairesinol or mixtures thereof, or ii) the phagocytes are cells of myeloid origin and the lignan is enterolactone or hydroxymatairesinol or mixtures thereof, or iii) the lymphocytes are T-lymphocytes and the lignan is hydroxymatairesinol, matairesinol or enterolactone or mixtures thereof. Furthermore, this invention concerns a method of treating or preventing an acute ischemia-reperfusion injury or a chronic condition, caused by overactivity of phagocytes or lymphocytes in an individual, said method comprising decreasing the activity of phagocytes in an individual by administering to said individual an effective amount of a lignan.

The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for members of the immunoglobulin (Ig) and / or toll-like receptor superfamilies that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering MSCs, including BMMSCs.

A placenta original filled stem cell and its production are disclosed. The process is carried out by bleeding after delivering placenta from uterus, perfusing to obtain single-cell soliquoid from continuous perfusion method or collagenase digestion method and acquiring filled stem cell from gradient and density centrifugation or immune magnetic bead separation. It has better external enrichment potentiality and multidirectional differential potentiality and low immunogenicity.

The invention relates to stems cells derived from bone marrow, and uses thereof in tissue regeneration.

Methods are provided for treating and / or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.

The present invention relates to a method for inducing differentiation of bone marrow-derived mesenchymal stem cells into mature neurons by culturing them in an optimal medium supplemented with necessary composition. According to the pre-induction method of the invention and a method for inducing differentiation of mesenchymal stem cells into neurons by culturing them in neuronal induction media (NIM) containing butyl hydroxyanisole, forskolin and VPA, mesenchymal stem cells can be effectively differentiated into neurons or motor neurons, which thereby can be effectively used as a therapeutic agent for cell therapy for neurodegenerative diseases.

The present invention for the first time demonstrated that:(1) bone marrow-derived pluripotent tissue stem cells can be induced in peripheral blood by intravenously administering tissue extract prepared from isolated skin pieces;(2) the substance in the isolated skin pieces, which is responsible for mobilizing bone marrow-derived pluripotent tissue stem cells to peripheral blood, is HMGB1; and(3) HMGB1 with the activity of mobilizing bone marrow-derived pluripotent stem cells to peripheral blood can be easily purified from cultured cells.

The invention discloses ginseng derived nano-particles, as well as a preparation method and application thereof. The ginseng derived nano-particles have a membrane structure, wherein the particle size range is 150 to 500nm, and the peak particle size is 280 to 350nm. The ginseng derived nano-particle is prepared by performing centrifugation and filtering impurity removal for many times. By the ginseng derived nano-particle, a bone marrow derived monocyte-macrophage can be effectively induced to be proliferated and activated, meanwhile, multiple surfactant molecules such as a TLR2 / 4 (toll-like receptor 2 / 4) and a CD80 (cluster of differentiation 80) are up-regulated, and cell factors such as a TNF-a (tumor necrosis factor-a) and an IL-6 (interleukin-6) are secreted. The ginseng derived nano-particle has broad application prospect in development of a medicament for preparing a natural immunoenhancer.

Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. 1). Antibodies against ubiquitin are shown to inhibit tumor cell migration.

The invention provides a fluorescence labeled human triple-negative breast cancer osseous metastasis cell line. The fluorescence labeled human triple-negative breast cancer osseous metastasis cell line is prepared with a method as follows: a human triple-negative breast cancer cell MDA-MB-231 is cultured; a lentivirus carrier containing RFP (red fluorescence protein) is amplified, and an RFP labelled MDA-MB-231 cell is prepared; the RFP-MDA-MB-231 cell is transplanted to the fourth pair breast fat pad position of a nude mouse and grows into tumor; shin bone of a hind limb is taken after 4-6 weeks, bone marrow is flushed with a buffer solution and digested with collagenase, a single cell from the bone marrow is obtained, in-vitro culture amplification is performed, and red fluorescence cells are sorted with a flow cytometry; through tumor formation screening in a body of the nude mouse, the red fluorescence labelled MDA-MB-231 human triple-negative breast cancer osseous metastasis cellline is obtained. The human triple-negative breast cancer osseous metastasis cell line has the characteristics of osseous metastasis, is labelled by fluorescent protein and realizes visualization andtraceability.

The present invention is based on the unexpected discovery that the loss of cells in inflamed tissue during chronic inflammation leads to the influx and long-term re-population of the tissue with bone marrow derived stem cells, and that it is these stem cells that are the primary source of metaplasia and cancer. Accordingly, the invention relates to various methods, reagents and kits for prognosing, diagnosing, staging, monitoring, preventing and treating cancers, particularly cancers associated with chronic inflammation.

The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.

Disclosed is a new use of a stem cell generator in preparation of bone defect repair materials, wherein the stem cell generator is formed by implanting a biomaterial with osteogenic induction capability or a biomaterial loaded with active substances and / or cells into an animal or a human body and generating organoids after development, the active substances are bone morphogenetic protein-2, or bone morphogenetic protein-7, other growth factors / polypeptides having bone regeneration induction ability, growth factors / polypeptide combinations, or a combination thereof. The cells are bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells or other derived mesenchymal stem cells; other types of cells with osteogenic differentiation capability; cells that aid in osteogenic differentiation of mesenchymal stem cells, such as vascular endothelial cells and the like. The stem cell generator is used to prepare bone repair materials for treatment of various types of bone defects or bone deformities that are spontaneous or caused by trauma.

The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.

The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof.

A method is described for generating a novel cancer stem cell line that possesses characteristics associated with stem cells, by co-culturing a human immortalized cell line and bone marrow-derived mesenchymal stem cells, and the novel cancer stem cell line established thereby. This method is able to readily generate cancer stem cells that are low in the level of structural chromosomal aberrations and are excellent in oncogenicity, and is effectively applicable to the development of anti-cancer drugs and personalized drugs.

The invention belongs to the field of biological medicine, and relates to a macrophage exosome membrane coated bionic nanoparticle as well as a preparation method and application thereof, and the macrophage exosome membrane coated bionic nanoparticle is formed by an exosome membrane coated nanoparticle PLGA (at) Dnmt3aossmartsilencer; the exosome membrane is separated from M2 macrophages from bone marrow; and the nano-particle PLGA (at) Dnmt3aossmartsilencer is formed by co-emulsification of a polylactic acid-glycolic acid copolymer PLGA and Dnmt3aossmartsilencer. Compared with the prior art, the application has the advantages that the EM-PLGA-(at) Dnmt3aossmartsilencer is used for remarkably inhibiting polarization of M2 macrophages in the allergic asthma (AA), the bionic medicine is effectively accumulated in the lung and promotes gene silencing, and meanwhile, the infiltration degree of inflammatory cells to the airway is reduced. Therefore, the PLGA NP based on the M2 macrophage exosome membrane is beneficial to delivery of the therapeutic Dnmt3aossmartsilencer to the airway, and the therapeutic Dnmt3aossmartsilencer is guided to be more effective in treatment in an AA mouse model.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention discloses a mouse fibroblast tumor cell strain HXLyAF-KBM and application thereof.The cell strain is derived from the bone marrow microenvironment in a human lymphoma cell nude mouse transplantation tumor model, the cell name of the cell strain is mouse lymphoma related fibroblast tumor cells HXLyAF-KBM, the preservation number is CCTCC NO: C2021106, the preservation date is December 9, 2021, and the preservation number is CCTCC NO: C2021106. The preservation unit is China Center for Type Culture Collection. The cell strain is a bone marrow-derived lymphoma-related mouse fibroblast tumor cell strain established for the first time at home and abroad, and can be applied to construction of a mouse fibroblast tumor animal model, a malignant bone marrow microenvironment model, a 3D tumor culture system and organoid system model, and a bone marrow microenvironment and lymphoma progress and drug resistance relationship model.

The invention provides dog mesenchymal stem cell injection and a preparation method and application thereof. The dog mesenchymal stem cell injection comprises dog mesenchymal stem cells, heparin calcium, dog blood albumin and an electrolyte solution. The mesenchymal stem cells from dog bone marrow are utilized ingeniously, and combined with other compositions to be prepared into an injection form, namely the dog mesenchymal stem cell injection. The traditional therapeutic method for a dog skin tissue injury is broken. A stem cell therapy is brought in the field of pet medical treatment, the dog mesenchymal stem cell injection has the advantages that stability is high, the curative effect is good, usage is safe, long-term preservation and transportation are achieved, no toxic and side effect exists, and the foundation is laid for large-scale clinic use.

The invention relates to the technical field of medicine and relates to a use of cis-platinum and particularly relates to a use of cis-platinum in high-level granulocyte-like myeloid derived suppressor cell (G-MDSC) bladder cancer treatment and a treatment method. In-vitro experiment and in-vivo animal experiment results show that the amount of G-MDSC in a bladder cancer focus is significantly increased than that of G-MDSC in a paracancerous control group and the amount of CD8+T in a bladder cancer focus is reduced than that of CD8+T in the control group so that an immunosuppressive microenvironment is induced and formed and the establishment and growth of bladder cancer are promoted. The cis-platinum chemotherapy can significantly inhibit the progress of bladder cancer caused by abnormal increasing of G-MDSC and can be further used for high level G-MDSC bladder cancer treatment.

The invention provides a separation method for hepatic inherent and infiltrating macrophages. The separation method comprises the following steps of (1) establishing and identifying mouse allogeneicbone marrow transplantation model, wherein a surface marker of a mononuclear macrophage of a recipient mouse is CD45.2, and a surface marker of a mononuclear macrophage of a donor mouse is CD45.1; (2)observing and irradiating the influence on hepatic parenchymal cells and inherent macrophages with an IHC method and a flow cytometry; and (3) irradiating a mononuclear cell of a mouse liver in a transplantation group with primary isolation, and sorting the hepatic inherent and infiltrating macrophages with the flow cytometry according to the surface marker of the mononuclear macrophage of the donor mouse, and describing the quantities, distribution and phenotypes of the hepatic inherent and infiltrating macrophages. In the separation method provided by the invention, by removing the CD45.2 recipient mouse bone marrow derived macrophages by irradiation and supplementing and replacing bone marrow cells of the recipient mouse with CD45.1 donor mouse bone marrows, the bone marrow derived infiltrating macrophages and the bone marrow derived inherent macrophages have different molecular phenotypes and achieves the effect of accurately and efficiently separating different hepatic macrophages.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention discloses a method for improving in-vitro development efficiency of porcine cloned embryos. The method comprises the following steps of: performing molecular identification on bone marrow-derived mesenchymal stem cells, and establishing a method capable of identifying the purity of the cells by using a few cells through a 6-channel flow type technology; performing gene modification on the porcine bone marrow mesenchymal stem cells to obtain porcine bone marrow mesenchymal stem cells for expressing multiple reprogramming factors; and separating out positive porcine bone marrow mesenchymal stem cells by using a fluorescent flow type separation method, continuously culturing the positive porcine bone marrow mesenchymal stem cells for 3 to 7 days, performing nuclear transfer on the cultured cells serving as nuclear donor cells, and studying the influence of 4RFs-3days, 6RFs-3days, 4RFs-7days and 6RFs-7days pMSC serving as nuclear donor cells on the improvement of the development efficiency of the porcine cloned embryos. The results show that the 4RFs-7days pMSC can well promote fission of the cloned embryos and formation of blastospheres, the cloned embryos can form a homogeneous state with uniform cell quantity, and a foundation is laid for efficiently cloning adult high-quality pig varieties in large scale.

The invention relates to highly proliferative stem cell obtained from menstrual fluid. The menstrual stern cells (MenSCs) may be cultured in vitro and exhibit mesenchymal stem cell (MSC)-like properties and some culture and expansion advantages. This population of MenSCs, compared to the broadly studied bone marrow derived stem cells (BM-MSCs) out-performs bone marrow derived mesenchymal stem cells in proliferation rate and support of hematopoietic stem cell (HSC) expansion in vitro. MenSCs demonstrate to maintain their stem cell properties over 2 years, being genetically stable, without expressing surface differentiation markers, and they also show the ability to differentiate into adipocytes, chondrocytes and osteoblast cells. MenSCs can be easily and periodically obtained, isolated and cultured.

The invention discloses a preparation method of iPSCs-derived MSCs. The preparation method comprises the following steps of culturing iPSCs; digesting the iPSCs, and performing suspension culture on digested iPSCs cells so as to form an embryoid body; adding an induced culture medium combination A in the suspension culture process of the embryoid body for induction and disintegration; and after the embryoid body is disintegrated, performing direct adherence culture, or after the embryoid body is digested, performing adherence culture, or after the embryoid body is digested, performing sortingculture to obtain the MSCs. The invention also discloses an application of the iPSCs-derived MSCs. The novel method for quickly preparing the iPSCs-derived MSCs disclosed by the invention has the characteristics that xenogeneic exogenous substances do not exist, the suspension culture is performed, the culture period is shorter, the operation is simple, infinite amplification is achieved, the efficiency is high, and the preparation method is more suitable for large-scale production. The obtained iPSCs-derived MSCs conforms to essential features of the MSCs through identification, besides, hasfunctions being similar to those of bone marrow derived MSCs, and can be used for tissue repair and treatment of immunization relevant diseases.

The invention relates to separation and purification of placental derived mesenchymal stem cells and belongs to the field of stem cell and tissue engineering. The efficient preparation method includes: with the consent of the parturient and her family, placing the placenta after caesarean birth of the parturient in a storage solution with a variety of antibioctics for a short period of time; crushing the placental after repeatedly cleaning blood and water of the placental in a laboratory, digesting by collagenase and patting with a homogenizer to obtain a cell suspension; using a density gradient centrifugation method to obtain the placental mesenchymal stem cells. The method for separating the placental derived mesenchymal stem cells with the homogenizer is multiple times higher than thatof traditional methods, the hydrolysis time is reduced, and the success rate is improved; the obtained mesenchymal stem cells have similar amplification capability and multifunctional differentiationpotential with bone marrow derived mesenchymal stem cells in vitro and are potential seed cell sources for tissue engineering and cell therapy, thereby having important clinical significance.

The invention discloses application of a TNFSF15 protein as a macrophage immunopotentiator and an activation method of the TNFSF15 protein, and belongs to the technical field of medicines, in the application, the TNFSF15 protein can activate mouse M-CSF or GM-CSF induced bone marrow-derived macrophages, mouse peritoneal macrophages and a macrophage line Raw264.7 into M1 type in vitro, so that the tumor cell killing function of the macrophages, the mouse peritoneal macrophages and the macrophage line Raw264.7 is enhanced; in addition, the TNFSF15 protein can enhance the immunocompetence of macrophages and inhibit tumor growth in vivo, and a new thought can be provided for clinical tumor treatment in the future.

The invention relates to a method for inducing iPSCs or ESCs to be differentiated into brown fat cells. The invention discloses a preparation method of iPSCs-derived MSCs. The method comprises the following steps: cultivating the iPSCs; digesting the iPSCs and performing suspension culture on the digested iPSCs cells to form an embryoid body; adding inducing medium combination A in the suspensionculture process of the embryoid body to induce differentiation; and directly performing adherent culture after the embryoid body is differentiated, or performing adherent culture after digestion or performing sorting culture after digestion to obtain the MSCs. The invention also discloses application of the iPSCs-derived MSCs. The novel method for rapidly preparing the iPSCs-derived MSCs has the characteristics of no foreign matters, suspension culture, shorter culture period, simplicity in operation, infinite amplification and the like, has high efficiency and is more suitable for large-scaleproduction. The iPSCs-derived MSCs accord with the basic characteristic of the MSCs through identification, have a function similar to the marrow-derived MSCs, and can be applied to tissue repair andtreatment on immune-related diseases.